Edition:
United Kingdom

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

4.23USD
19 Jan 2018
Change (% chg)

$-0.03 (-0.70%)
Prev Close
$4.26
Open
$4.27
Day's High
$4.28
Day's Low
$4.12
Volume
4,006
Avg. Vol
11,416
52-wk High
$9.32
52-wk Low
$1.96

Latest Key Developments (Source: Significant Developments)

Biomerica Q2 Loss Per Share $0.03
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Biomerica Inc ::BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER.Q2 LOSS PER SHARE $0.03.Q2 SALES ROSE 12.7 PERCENT TO $1.614 MILLION.  Full Article

China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Biomerica Inc ::CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER.  Full Article

Biomerica extends license agreement with Celtis Pharm
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Biomerica Inc ::Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019.Biomerica Inc - has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea​.Biomerica - ‍term of exclusivity agreement is five years with an additional two years for telcon to receive Korean FDA clearance​.Biomerica - agreement may be cancelled if co has not obtained final clearance for sale of products in U.S. from FDA on or before December 31, 2019​.  Full Article

Biomerica Inc Q1 ‍net sales $1.4 million
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Biomerica Inc :Net sales of $1.4 million for three months ending August 31, 2017, an increase of 2.4%​.Net loss for three months ended August 31, 2017 was $207,059 compared to a net loss of $55,417 during same period in fiscal 2017​.  Full Article

BRIEF-Biomerica Q2 Loss Per Share $0.03

* BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER